The Promise of Precision Medicine

Aug 26, 2016 | Blogs, Life Science Research, Proteomics | 0 comments

NIH awards $55 million to build million-person precision medicine study

Here is the latest update on the Worldwide Efforts to Accelerate Precision Medicine

The NIH recently issued a press release in early July announcing $55 million in awards. According to the release, the $55 million award in the fiscal year 2016 will go towards building the foundational partnerships and infrastructure needed to launch the Cohort Program of President Obama’s Precision Medicine Initiative (PMI). The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment, and genetics.

The press release goes on the state that the PMI Cohort Program is one of the most ambitious research projects in history and will set the foundation for new ways of engaging people in research. PMI volunteers will be asked to contribute a wide range of health, environment and lifestyle information. They will also be invited to answer questions about their health history and status, share their genomic and other biological information through simple blood and urine tests and grant access to their clinical data from electronic health records. Also, mobile health devices and apps will provide lifestyle data and environmental exposures in real time.  All of this will be accomplished with essential privacy and security safeguards.  As partners in the research, participants will have ongoing input into study design and implementation, as well as access to a wide range of their individual and aggregated study results.

The SCIEX Solution
As the promise of precision medicine continues to evolve; researchers will need powerful tools and application support to perform the Omics research at an industrialized scale that is sufficient to build the scientific foundation of precision medicine.

SCIEX has been focused on industrializing the proteomics solutions to enable large-scale proteome studies to advance research.   Centered around the microflow SWATH® acquisition strategy for collecting digital proteome maps, data processing has been moved to the cloud with the OneOmics™ project to provide the compute power for processing these maps.  Protocols also have been automated to provide the reproducibility required, again at an appropriate scale to feed the pipeline.

The same principles have been applied to industrializing quantitative lipidomics, with the launch of the Lipidyzer™ Platform.

With SCIEX technologies, you can accelerate the pace of your research to identify key genes, proteins, lipids and metabolites in complex systems biology and then integrate your findings to gain a comprehensive insight to further understand health and disease.

Want to know more about available methods? Comment below!

References

  1. NIH Press Release- NIH awards $55 million to build million-person precision medicine study

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network